MMP-2-triggered, Mitochondria-targeted PROTAC-PDT Therapy of Breast Cancer and Brain Metastases Inhibition

Overview

Journal Nat Commun

Specialty Biology

Date 2024 Nov 29

PMID 39613781

Authors

Fan Tong

Yufan Wang

Yanyan Xu

Yang Zhou

Siqin He

Yufan Du

Wenqin Yang

Ting Lei

Yujun Song

Tao Gong

Huile Gao

Affiliations

Soon will be listed here.

Abstract

Proteolytic targeting chimera (PROTAC) technology is a protein-blocking technique and induces antitumor effects, with potential advantages. However, its effect is limited by insufficient distribution and accumulation in tumors. Herein, a transformable nanomedicine (dBET6@CFMPD) with mitochondrial targeting capacity is designed and constructed to combine PROTAC with photodynamic therapy (PDT). In this work, we demonstrate that dBET6@CFMPD exhibits great biodistribution and retention, and can induce potent antitumor response to suppress primary and metastatic tumors, becoming a nanomedicine with potential in cancer combination therapy.

References

Liao Y, Wu Y, Long X, Zhu S, Jin C, Xu J . High level of BRD4 promotes non-small cell lung cancer progression. Oncotarget. 2016; 7(8):9491-500. PMC: 4891054. DOI: 10.18632/oncotarget.7068. View

Liu J, Chen H, Liu Y, Shen Y, Meng F, Umit Kaniskan H . Cancer Selective Target Degradation by Folate-Caged PROTACs. J Am Chem Soc. 2021; 143(19):7380-7387. PMC: 8219215. DOI: 10.1021/jacs.1c00451. View

Xiong W, Qi L, Jiang N, Zhao Q, Chen L, Jiang X . Metformin Liposome-Mediated PD-L1 Downregulation for Amplifying the Photodynamic Immunotherapy Efficacy. ACS Appl Mater Interfaces. 2021; 13(7):8026-8041. DOI: 10.1021/acsami.0c21743. View

Wu C, Jiao Q, Wang C, Zheng Y, Pan X, Zhong W . Nanofibrillar peptide hydrogels for self-delivery of lonidamine and synergistic photodynamic therapy. Acta Biomater. 2022; 155:139-153. DOI: 10.1016/j.actbio.2022.11.008. View

Zhang H, Peng R, Chen S, Shen A, Zhao L, Tang W . Versatile Nano-PROTAC-Induced Epigenetic Reader Degradation for Efficient Lung Cancer Therapy. Adv Sci (Weinh). 2022; 9(29):e2202039. PMC: 9561860. DOI: 10.1002/advs.202202039. View

Maeda H . Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev. 2015; 91:3-6. DOI: 10.1016/j.addr.2015.01.002. View

Habibi N, Kamaly N, Memic A, Shafiee H . Self-assembled peptide-based nanostructures: Smart nanomaterials toward targeted drug delivery. Nano Today. 2016; 11(1):41-60. PMC: 4834907. DOI: 10.1016/j.nantod.2016.02.004. View

He S, Gao F, Ma J, Ma H, Dong G, Sheng C . Aptamer-PROTAC Conjugates (APCs) for Tumor-Specific Targeting in Breast Cancer. Angew Chem Int Ed Engl. 2021; 60(43):23299-23305. DOI: 10.1002/anie.202107347. View

Ngambenjawong C, Gustafson H, Pun S . Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv Drug Deliv Rev. 2017; 114:206-221. PMC: 5581987. DOI: 10.1016/j.addr.2017.04.010. View

10.

Burslem G, Crews C . Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery. Cell. 2020; 181(1):102-114. PMC: 7319047. DOI: 10.1016/j.cell.2019.11.031. View

11.

Kumar A, Morales O, Mordon S, Delhem N, Boleslawski E . Could Photodynamic Therapy Be a Promising Therapeutic Modality in Hepatocellular Carcinoma Patients? A Critical Review of Experimental and Clinical Studies. Cancers (Basel). 2021; 13(20). PMC: 8534013. DOI: 10.3390/cancers13205176. View

12.

Donati B, Lorenzini E, Ciarrocchi A . BRD4 and Cancer: going beyond transcriptional regulation. Mol Cancer. 2018; 17(1):164. PMC: 6251205. DOI: 10.1186/s12943-018-0915-9. View

13.

Wang F, Dong G, Ding M, Yu N, Sheng C, Li J . Dual-Programmable Semiconducting Polymer NanoPROTACs for Deep-Tissue Sonodynamic-Ferroptosis Activatable Immunotherapy. Small. 2023; 20(8):e2306378. DOI: 10.1002/smll.202306378. View

14.

Zhu X, Liu W, Tang X, Chen Y, Ge X, Ke Q . The BET PROTAC inhibitor dBET6 protects against retinal degeneration and inhibits the cGAS-STING in response to light damage. J Neuroinflammation. 2023; 20(1):119. PMC: 10201800. DOI: 10.1186/s12974-023-02804-y. View

15.

Ren C, Xu X, Yan D, Gu M, Zhang J, Zhang H . Dual-action nanoplatform with a synergetic strategy to promote oxygen accumulation for enhanced photodynamic therapy against hypoxic tumors. Acta Biomater. 2022; 146:465-477. DOI: 10.1016/j.actbio.2022.04.035. View

16.

Keir M, Butte M, Freeman G, Sharpe A . PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26:677-704. PMC: 10637733. DOI: 10.1146/annurev.immunol.26.021607.090331. View

17.

Deng K, Li C, Huang S, Xing B, Jin D, Zeng Q . Recent Progress in Near Infrared Light Triggered Photodynamic Therapy. Small. 2017; 13(44). DOI: 10.1002/smll.201702299. View

18.

Ovais M, Guo M, Chen C . Tailoring Nanomaterials for Targeting Tumor-Associated Macrophages. Adv Mater. 2019; 31(19):e1808303. DOI: 10.1002/adma.201808303. View

19.

Yang C, Yang Y, Li Y, Ni Q, Li J . Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors. J Am Chem Soc. 2022; 145(1):385-391. DOI: 10.1021/jacs.2c10177. View

20.

Castano A, Mroz P, Hamblin M . Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer. 2006; 6(7):535-45. PMC: 2933780. DOI: 10.1038/nrc1894. View